US FDA defends approval of Alzheimer's disease drug

Lancet. 2021 Jul 3;398(10294):12. doi: 10.1016/S0140-6736(21)01455-0.
No abstract available

Publication types

  • News

MeSH terms

  • Alzheimer Disease / drug therapy*
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Drug Approval*
  • Humans
  • United States
  • United States Food and Drug Administration

Substances

  • Antibodies, Monoclonal, Humanized
  • aducanumab